The U.S. Food and Drug Administration placed a clinical hold on Tryp Therapeutics’ Phase IIa trial for eating disorders, including binge eating disorder and hypothalamic obesity.
https://www.pharmalive.com/wp-content/uploads/2021/10/Tryp-Therapeutics-Stumbles-as-FDA-Halts-Eating-Disorder-Study-BioSpace-10-22-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-10-22 11:50:492021-10-22 14:35:06Tryp Therapeutics Stumbles as FDA Halts Eating Disorder Study